Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on December 15, 2025. The filing details the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement of equity securities.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 207,374 shares of Common Stock and unregistered warrants to purchase up to 414,748 shares of Common Stock.
- Offering Price: $10.85 per share.
- Gross Proceeds: Approximately $2.2 million.
- Warrant Terms: Exercise price of $10.60 per share; exercisable immediately; expire two years following the effective date of the resale registration statement.
- Placement Agent Fees: 7.0% cash fee, 1% management fee, $10,000 non-accountable expenses, and $10,000 clearing fees.
- Placement Agent Warrants: 13,479 warrants (6.5% of shares sold) with an exercise price of $13.5625 per share (125% of offering price).
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain investors. Key covenants include:
- Lock-Up Agreements: Directors and officers are subject to a 10-day lock-up period following the Closing Date.
- Issuance Restrictions: The Company agreed not to issue Common Stock or equivalents for 10 days post-closing and is prohibited from entering into Variable Rate Transactions for one year post-closing.
- ATM Facility: After the 10-day restriction period, the Company may utilize an at-the-market facility with H.C. Wainwright & Co., LLC.
- Registration Obligation: The Company must file a registration statement for the resale of warrant shares within 30 days and use commercially reasonable efforts to have it declared effective within 60 days.
Outlook, Risks, and Contingencies
The offering is expected to close on or about December 16, 2025, subject to customary closing conditions. The filing notes that the Common Warrants may only be exercised on a cashless basis if a registration statement is not available. Additionally, beneficial ownership is capped at 4.99% (increasable to 9.99% at the holder's election) to prevent excessive concentration. The filing does not provide specific operational guidance or risk factors beyond the standard terms of the securities purchase agreement.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received.
- Confirm the effective date of the Resale Registration Statement for the Common Warrant Shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific investor rights and covenants.
- Monitor the Company's cash position post-closing to assess runway for operations.
- Check for any subsequent filings regarding the utilization of the at-the-market facility.